The Covid-19 treatment molnupiravir was developed using funding from the National Institutes of Health and the Department of Defense. A FIVE-DAY COURSE of molnupiravir, the new medicine being hailed as a “huge advance” in the treatment of...

At the Interim Analysis, 7.3 Percent of Patients Who Received Molnupiravir Were Hospitalized Through Day 29, Compared With 14.1 Percent of Placebo-Treated Patients Who were Hospitalized or Died Merck Plans to Seek Emergency Use Authorization...